BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sayad B, Sobhani M, Khodarahmi R. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial? Arch Med Res. 2020;51:577-581. [PMID: 32387040 DOI: 10.1016/j.arcmed.2020.04.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res. 2020;19:4690-4697. [PMID: 32692185 DOI: 10.1021/acs.jproteome.0c00392] [Cited by in Crossref: 59] [Cited by in F6Publishing: 79] [Article Influence: 29.5] [Reference Citation Analysis]
2 de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. COVID-19 therapy: What weapons do we bring into battle? Bioorg Med Chem 2020;28:115757. [PMID: 32992245 DOI: 10.1016/j.bmc.2020.115757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Krumm ZA, Lloyd GM, Francis CP, Nasif LH, Mitchell DA, Golde TE, Giasson BI, Xia Y. Precision therapeutic targets for COVID-19. Virol J 2021;18:66. [PMID: 33781287 DOI: 10.1186/s12985-021-01526-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hu S, Jiang S, Qi X, Bai R, Ye XY, Xie T. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. Drug Dev Res 2021. [PMID: 34762760 DOI: 10.1002/ddr.21895] [Reference Citation Analysis]
5 Liu D, Zeng X, Ding Z, Lv F, Mehta JL, Wang X. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. Front Pharmacol 2021;12:699949. [PMID: 34512335 DOI: 10.3389/fphar.2021.699949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Heilmann E, Costacurta F, Geley S, Mogadashi SA, Volland A, Rupp B, Harris RS, von Laer D. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun Biol 2022;5:391. [PMID: 35478219 DOI: 10.1038/s42003-022-03277-0] [Reference Citation Analysis]
7 Gogtay NJ, Sheth HJ, Maurya MR, Belhekar MN, Thatte UM. A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. J Postgrad Med 2021;67:134-8. [PMID: 34414930 DOI: 10.4103/jpgm.JPGM_77_21] [Reference Citation Analysis]
8 Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020;72:1479-508. [PMID: 32889701 DOI: 10.1007/s43440-020-00155-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 43.5] [Reference Citation Analysis]
9 Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, Morozova I, Kalachikov S, Kirchdoerfer RN, Russo JJ. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect 2020;8:e00674. [PMID: 33124786 DOI: 10.1002/prp2.674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
10 Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A, Khosravi Shadmani F, Bozorgomid A, Zamanian MH, Afsharian M. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother 2021;76:2158-67. [PMID: 34037760 DOI: 10.1093/jac/dkab152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect 2021;42:100895. [PMID: 33976895 DOI: 10.1016/j.nmni.2021.100895] [Reference Citation Analysis]
12 Lundstrom K. Coronavirus pandemic: treatment and future prevention. Future Microbiol 2020;15:1507-21. [PMID: 33140657 DOI: 10.2217/fmb-2020-0174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 El-Shorbagy HI, Belal F. Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units. Spectrochim Acta A Mol Biomol Spectrosc 2022;267:120623. [PMID: 34810100 DOI: 10.1016/j.saa.2021.120623] [Reference Citation Analysis]
14 Gupta R, Dhamija P. Sofosbuvir for COVID-19 infection: A potential candidate. Indian J Pharmacol 2020;52:232-3. [PMID: 32874010 DOI: 10.4103/ijp.IJP_675_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Bagheri M, Niavarani A. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2020.1830854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, Fazlinejad R, Mohammadi-Samani S, Firouzabadi N, Hosseini M, Farjadian F. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol 2021;16:1415-51. [PMID: 34812049 DOI: 10.2217/fmb-2021-0116] [Reference Citation Analysis]
17 Pirzada RH, Haseeb M, Batool M, Kim M, Choi S. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells 2021;10:1052. [PMID: 33946869 DOI: 10.3390/cells10051052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kow CS, Javed A, Ramachandram D, Hasan SS. Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Rev Anti Infect Ther 2021;:1-9. [PMID: 34719324 DOI: 10.1080/14787210.2022.2000861] [Reference Citation Analysis]
19 Pokorska-Śpiewak M, Śpiewak M. Management of hepatitis C in children and adolescents during COVID-19 pandemic. World J Hepatol 2020; 12(8): 485-492 [PMID: 32952875 DOI: 10.4254/wjh.v12.i8.485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Tarasova O, Ivanov S, Filimonov DA, Poroikov V. Data and Text Mining Help Identify Key Proteins Involved in the Molecular Mechanisms Shared by SARS-CoV-2 and HIV-1. Molecules 2020;25:E2944. [PMID: 32604797 DOI: 10.3390/molecules25122944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yadav R, Imran M, Dhamija P, Chaurasia DK, Handu S. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2. J Biomol Struct Dyn 2020;:1-16. [PMID: 32715956 DOI: 10.1080/07391102.2020.1796812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, Kalachikov S, Russo JJ, Ju J. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10:16577. [PMID: 33024223 DOI: 10.1038/s41598-020-73641-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
23 Mongia A, Saha SK, Chouzenoux E, Majumdar A. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci Rep 2021;11:9047. [PMID: 33907209 DOI: 10.1038/s41598-021-88153-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Koulgi S, Jani V, Uppuladinne MVN, Sonavane U, Joshi R. Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2. RSC Adv 2020;10:26792-803. [DOI: 10.1039/d0ra04743k] [Cited by in Crossref: 23] [Article Influence: 11.5] [Reference Citation Analysis]
25 Anand J, Ghildiyal T, Madhwal A, Bhatt R, Verma D, Rai N. Computational guided approach for drug repurposing against SARS-CoV-2. Future Virology 2021;16:211-43. [DOI: 10.2217/fvl-2020-0403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Harrell CR, Jovicic BP, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Anal Cell Pathol (Amst) 2020;2020:1939768. [PMID: 33274176 DOI: 10.1155/2020/1939768] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 Liu CH, Lu CH, Wong SH, Lin LT. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. Front Immunol 2020;11:616595. [PMID: 33613542 DOI: 10.3389/fimmu.2020.616595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Aghamirza Moghim Aliabadi H, Eivazzadeh‐keihan R, Beig Parikhani A, Fattahi Mehraban S, Maleki A, Fereshteh S, Bazaz M, Zolriasatein A, Bozorgnia B, Rahmati S, Saberi F, Yousefi Najafabadi Z, Damough S, Mohseni S, Salehzadeh H, Khakyzadeh V, Madanchi H, Kardar GA, Zarrintaj P, Saeb MR, Mozafari M. COVID‐19: A systematic review and update on prevention, diagnosis, and treatment. MedComm 2022;3. [DOI: 10.1002/mco2.115] [Reference Citation Analysis]
29 Zafar S, Arshad MS, Fatima S, Ali A, Zaman A, Sayed E, Chang MW, Ahmad Z. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics 2020;12:E945. [PMID: 33023033 DOI: 10.3390/pharmaceutics12100945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Taher M, Tik N, Susanti D. Drugs intervention study in COVID-19 management. Drug Metabolism and Personalized Therapy 2021;0:20200173. [DOI: 10.1515/dmdi-2020-0173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Torti C, Mazzitelli M, Trecarichi EM, Darius O. Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now? BMC Infect Dis 2020;20:412. [PMID: 32536344 DOI: 10.1186/s12879-020-05147-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol 2021;34:625-33. [PMID: 34475732 DOI: 10.20524/aog.2021.0628] [Reference Citation Analysis]
33 Luo W, Ige OO, Beacon TH, Su RC, Huang S, Davie JR, Lakowski TM. The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. Genome 2021;64:400-15. [PMID: 33197212 DOI: 10.1139/gen-2020-0130] [Reference Citation Analysis]
34 Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61 [PMID: 33816150 DOI: 10.5501/wjv.v10.i2.53] [Reference Citation Analysis]
35 Shende P, Khanolkar B, Gaud RS. Drug repurposing: new strategies for addressing COVID-19 outbreak. Expert Rev Anti Infect Ther 2021;19:689-706. [PMID: 33183102 DOI: 10.1080/14787210.2021.1851195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Long MJC, Aye Y. Science's Response to CoVID-19. ChemMedChem 2021;16:2288-314. [PMID: 33811458 DOI: 10.1002/cmdc.202100079] [Reference Citation Analysis]
37 Karnik M, Beeraka NM, Uthaiah CA, Nataraj SM, Bettadapura ADS, Aliev G, Madhunapantula SV. A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Mol Neurobiol 2021. [PMID: 34089508 DOI: 10.1007/s12035-021-02399-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]